Skip to main content
| News

Bionter receives 3 million US dollars in investments

28.04.2022

Bionter AG has received 3 million US dollars in a seed funding round. These funds will enable Bionter to bring to market its technology for counting sub-visible particles in liquid biologics this year.

Bionter, a company based in Riehen in the canton of Basel-Stadt, has raised its capital cover by a total of 3 million US dollars. The seed funding round for the Basel-based expert in testing sub-visible particles in liquid biologics was led by the venture capital company Dynamk Capital based in New York.

According to a press release, this funding accelerates the “already exceptional momentum” of Bionter’s first product. This comprehensive solution involves a particle counter with single-use consumables, maintenance, and training. It is suitable for use in the pharmaceuticals sector and is based on a new combination of light obscuration technology and smart automation.

On the market at the end of 2022

Bionter’s device aims to minimize the number of costly samples used to determine the particle count, increase efficiency, and reduce human interaction. According to the information provided, this improves the reliability of measurements, data integrity, and thus patient safety. Development for this patented technology has been concluded. It is expected to come to market at the end of 2022.

Bionter CEO Dr. Tobias Werk states: “This financing enables us to bring our first product to our customers while driving the development of new innovations. We are thrilled to have Dynamk Capital join our team, as they provide a wealth of experience growing life science tools companies and help position Bionter and help us to make our vision a reality.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Databaum establishes headquarters in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
New innovation campus opens in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
VectivBio raises 125 million US dollars in stock sale
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio raises 125 million US dollars in stock sale

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.